These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 38166148

  • 1. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J, Lan T, Lu H, Pan J.
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [Abstract] [Full Text] [Related]

  • 2. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
    Zhou J, Lu H, Pan J.
    Int J Health Policy Manag; 2024 Jan; 13():8150. PubMed ID: 38618837
    [Abstract] [Full Text] [Related]

  • 3. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
    Zhang Y, Wei Y, Li H, Chen Y, Guo Y, Han S, Shi L, Guan X.
    Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
    [Abstract] [Full Text] [Related]

  • 4. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
    Mingge X, Jingyu W, Qi L, Zhe Z, Qing R.
    Inquiry; 2023 Jul; 60():469580231170729. PubMed ID: 37171066
    [Abstract] [Full Text] [Related]

  • 5. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
    Bao Y, Liu Y, Ma R, Zhang P, Li X.
    J Glob Health; 2023 Nov 09; 13():04140. PubMed ID: 37934965
    [Abstract] [Full Text] [Related]

  • 6. Progress on drug pricing negotiations in China.
    Tang M, Song P, He J.
    Biosci Trends; 2020 Jan 20; 13(6):464-468. PubMed ID: 31875587
    [Abstract] [Full Text] [Related]

  • 7. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
    Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R, Traversa G, Perrone F, Martini N, Gyawali B, Addis A.
    BMJ Open; 2019 Dec 10; 9(12):e033728. PubMed ID: 31826897
    [Abstract] [Full Text] [Related]

  • 8. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
    Huang C, Ung COL, Wushouer H, Bai L, Huang T, Li X, Guan X, Shi L.
    Health Res Policy Syst; 2022 Jan 03; 20(1):3. PubMed ID: 34980159
    [Abstract] [Full Text] [Related]

  • 9. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis.
    Luo X, Du X, Huang L, Guo Q, Tan R, Zhou Y, Li Z, Xue X, Li T, Le K, Qian F, Chow SC, Yang Y.
    Lancet Reg Health West Pac; 2023 Mar 03; 32():100670. PubMed ID: 36785854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
    Luo Z, Gyawali B, Han S, Shi L, Guan X, Wagner AK.
    Semin Oncol; 2021 Apr 03; 48(2):141-144. PubMed ID: 33875231
    [Abstract] [Full Text] [Related]

  • 15. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A, Ciapponi A, Aaserud M, Vietto V, Austvoll-Dahlgren A, Kösters JP, Vacca C, Machado M, Diaz Ayala DH, Oxman AD.
    Cochrane Database Syst Rev; 2014 Oct 16; 2014(10):CD005979. PubMed ID: 25318966
    [Abstract] [Full Text] [Related]

  • 16. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, Michaeli DT.
    Breast Cancer; 2024 Nov 16; 31(6):1144-1155. PubMed ID: 39320645
    [Abstract] [Full Text] [Related]

  • 17. Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology.
    Michaeli DT, Michaeli T.
    Value Health; 2023 Nov 16; 26(11):1590-1600. PubMed ID: 37516196
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.